This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Myocardial Salvage and Contrast Dye Induced Nephropathy Reduction by N-Acetylcystein (LIPSIA-N-ACC)

This study has been completed.
Information provided by:
University of Leipzig Identifier:
First received: April 18, 2007
Last updated: July 7, 2008
Last verified: July 2008

Acetylcystein is a potent antioxidans which is able to prevent contrast dye induced nephropathy in stable patients undergoing additional hydration.

In primary percutaneous intervention for infarction hydration is not possible. Therefore Acetylcystein might prevent contrast dye induced nephropathy.

Furthermore, it might reduce infarct size as a result of its antioxidant properties.

Clinical trials are missing so far examining the effects of Acetylcystein on nephropathy and infarct size.

Condition Intervention Phase
Myocardial Infarction Drug: Acetylcystein Drug: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Trial to Compare Infarct Size and Occurrence of Contrast Dye Induced Nephropathy in Patients With Primary Percutaneous PCI in STEMI

Resource links provided by NLM:

Further study details as provided by University of Leipzig:

Primary Outcome Measures:
  • Myocardial salvage measured by magnetic resonance imaging [ Time Frame: 4 days ]
  • prevention of nephropathy [ Time Frame: 3 days ]

Secondary Outcome Measures:
  • ST-segment resolution [ Time Frame: 90 min ]
  • TIMI flow [ Time Frame: minutes ]
  • composite clinical endpoint (death, reinfarction, congestive heart failure) [ Time Frame: 30 days ]
  • need for dialysis [ Time Frame: 4 days ]
  • microvascular obstruction measured by magnetic resonance [ Time Frame: 4 days ]
  • infarct size measured by magnetic resonance [ Time Frame: 4 days ]
  • oxidative stress [ Time Frame: 72 hours ]

Enrollment: 251
Study Start Date: December 2006
Study Completion Date: June 2008
Primary Completion Date: February 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
High-dose N-Acetylcystein during percutaneous coronary intervention and for 2 days post intervention 2 x/day
Drug: Acetylcystein
high-dose N-Acetylcystein during PCI and for 2/day for 2 days
Placebo Comparator: 2
Placebo (NaCl)
Drug: Placebo
NaCl as placebo


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • ST-elevation infarction (<12 hours)
  • Angina

Exclusion Criteria:

  • Prior fibrinolysis
  • Dialysis
  • Pregnancy
  • Lactase-reduction
  • Glucose-galactose malabsorption
  • Known allergy to acetylcystein
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00463749

University of Leipzig - Heart Center
Leipzig, Germany, 04289
Sponsors and Collaborators
University of Leipzig
Study Chair: Holger Thiele, MD Heartcenter Leipzig GmbH
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):

Responsible Party: Holger Thiele, MD, University of Leipzig - Heart Center Identifier: NCT00463749     History of Changes
Other Study ID Numbers: 1111/2006
Study First Received: April 18, 2007
Last Updated: July 7, 2008

Keywords provided by University of Leipzig:
primary PCI
infarct size
ST-elevation myocardial infarction

Additional relevant MeSH terms:
Myocardial Infarction
Kidney Diseases
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Urologic Diseases processed this record on September 19, 2017